VGX Pharmaceuticals (Formerly Known as Viral Genomix, Inc.) Receives $1.9 Million Contract from U.S. Government to Develop Skin Micro-Electroporation for Improved Biodefense Vaccine Efficacy

BLUE BELL, Pa.--(BUSINESS WIRE)--VGX Pharmaceuticals announced today that it has been awarded a contract from the Defense Threat Reduction Agency (DTRA) to develop VGX’s constant current electroporation technology for intradermal (ID) delivery of DNA vaccines and therapeutics. The contract is for $1.9 Million over 12 months. Under the contract, VGX will demonstrate in vivo efficacy of novel vaccines derived from DNA plasmid-based pox virus antigens delivered using a skin micro-electroporation system.